Patents by Inventor Hsi-Chieh Wang

Hsi-Chieh Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating hypertension
    Patent number: 9744165
    Abstract: Dextromethorphan is used to lower blood pressure in a subject suffering from hypertension, alone or in combination with another anti-hypertensive agent. In particular, dextromethorphan acts synergistically with a calcium channel blocker, such as amlodipine, to result in a major improvement in the treatment of hypertension, with no or little adverse effects.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 29, 2017
    Assignee: TSH Biopharm Corporation Ltd.
    Inventors: Jaw-Wen Chen, Hsi-Chieh Wang, Shin-Yi Juang
  • METHOD FOR TREATING HYPERTENSION
    Publication number: 20160235741
    Abstract: Dextromethorphan is used to lower blood pressure in a subject suffering from hypertension, alone or in combination with another anti-hypertensive agent. In particular, dextromethorphan acts synergistically with a calcium channel blocker, such as amlodipine, to result in a major improvement in the treatment of hypertension, with no or little adverse effects.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 18, 2016
    Inventors: Jaw-Wen CHEN, Hsi-Chieh WANG, Shin-Yi JUANG
  • METHOD AND COMPOSITION FOR TREATING A DISEASE OR CONDITION RELATED TO OREXIN RECEPTOR 1, OREXIN RECEPTOR 2, SOMATOSTATIN RECEPTOR 2 OR DOPAMINE D2L RECEPTOR
    Publication number: 20130210911
    Abstract: Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.
    Type: Application
    Filed: October 25, 2010
    Publication date: August 15, 2013
    Applicant: CENTER LABORATORIES, INC.
    Inventors: Huai-Cheng Lee, Guang-Tzuu Shane, Hsi-Chieh Wang, Rong Jin Lin